A down payment of 350 million, totaling 8.5 billion USD! INNOVENT BIO collaborates with Eli Lilly to layout the research and development of new tumor immunotherapy drugs
Wallstreetcn·- Eli Lilly will pay 350 million USD in advance to Innovent Biologics for the joint development of new drugs targeting oncology and immunological diseases. - This partnership showcases a new model for collaboration between multinational pharmaceutical companies and Chinese biopharmaceutical firms that goes beyond traditional licensing agreements. - Innovent will utilize its antibody technology platform for drug development before the completion of Phase 2 clinical trials in China, while Eli Lilly will receive exclusive rights to commercialize the drugs outside Greater China.Analysis of the Impact of Hang Seng and Stock Connect Adjustments in the Third Quarter
Wallstreetcn·- The Hang Seng Index has announced its quarterly adjustments, including the addition of Innovent Biologics and Yum China, while removing New Energy, New Oriental-S, and Haidilao from the Hang Seng China Enterprises Index. - The adjustments will take effect on December 8, 2025, with passive funds expected to rebalance on December 5 to minimize tracking errors. - The changes are anticipated to positively impact stocks like Innovent Biologics and Yum China, while negatively affecting ASMPT and New Energy.